Controlling severe bleeding during complex surgical procedures remains one of the most critical challenges in modern medicine. In surgeries involving highly vascularized solid organs—such as hepatic resections—uncontrolled parenchymal bleeding significantly increases patient morbidity, prolongs operating times, and elevates postoperative complication rates. To combat this, advanced topical hemostatic agents have become indispensable tools in the operating theater. Among the most recent innovations in this field is , a novel pad-type hemostatic agent designed to deliver rapid, reliable localized bleeding control. What is Stopad®?
Achieved a 90.20% successful hemostasis rate within the same timeframe. stopad
As parenchymal surgeries and solid organ resections continue to rise globally due to expanding oncology treatments, tools like Stopad® will be crucial to improving patient outcomes. Future clinical updates are expected to explore the application of Stopad® across other surgical subspecialties, including partial nephrectomies, splenic trauma management, and cardiovascular procedures. Among the most recent innovations in this field
Embedded within the chitosan matrix is a bioengineered recombinant thrombin-like hemocoagulase enzyme. This component actively mimics the human body's natural thrombin behavior. It cleaves fibrinogen directly into fibrin monomers, bypassing several steps of the standard systemic coagulation pathway. This results in the rapid formation of a stable, localized fibrin clot right at the application site. Clinical Evidence: Stopad® vs. Tachosil® As parenchymal surgeries and solid organ resections continue
The trial enrolled undergoing open hepatic resection (liver surgery), a procedure notorious for high-volume parenchymal bleeding. Patients were randomized in a strict 1:1 ratio into two distinct surgical cohorts: Investigational Group: Received Stopad® (53 patients). Control Group: Received Tachosil® (51 patients). Key Findings